TOCILIZUMAB
Tracking # 20-1052508
$99999.00
There are no ratings for this course
Learn more Educator STATPEARLS PUBLISHING, LLC
CE Broker Reporting Reported automatically
Method Computer-Based Training
Course overview
TOCILIZUMAB IS FDA-INDICATED FOR THE ADULT TREATMENT OF RHEUMATOID ARTHRITIS AND GIANT CELL ARTERITIS AND PEDIATRIC TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. TOCILIZUMAB HAS A NON-FDA-INDICATED USE IN THE TREATMENT OF COVID-19 PNEUMONIA. THIS ACTIVITY HIGHLIGHTS THE ROLE OF THE INTERPROFESSIONAL TEAM IN MANAGING PATIENTS PRESCRIBED TOCILIZUMAB FOR RHEUMATOID ARTHRITIS, GIANT CELL ARTERITIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS.
Subject areas
This course counts toward the state boards and subject areas below.
Bahamas Medical Council
Specialty Medical Practitioner
1h
General Medicine
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
1h
Category I CME
Mississippi State Board of Medical Licensure
Medical Doctor
1h
AMA Category I
Physician Assistant
1h
AMA Category I
State Medical Board of Ohio
Doctor of Medicine
1h
AMA Category I